{
  "docId": "019de515-df71-7068-a98d-cc2a99c8892d",
  "docSlug": "c88233ba648814c9f5b65afc1926df6d",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 11,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/10",
  "deckHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d",
  "deckJsonHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json",
  "deckAnchorHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.076,
        "w": 0.847,
        "x": 0.082,
        "y": 0.293
      },
      "kind": "paragraph",
      "text": "Providing vulnerable populations, such as immunocompromised people, with protection from COVID-19 is a long-term, large opportunity",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a6e5368-5481-4c70-b070-8d68670147b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.076,
        "w": 0.847,
        "x": 0.082,
        "y": 0.733
      },
      "kind": "paragraph",
      "text": "Well capitalized with $333.4 million in cash, cash equivalents and marketable securities as of March 31, 2023 expected to support operating runway into second half of 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62fd68ff-fb8b-4306-9847-b68cc16a4e48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.076,
        "w": 0.847,
        "x": 0.082,
        "y": 0.513
      },
      "kind": "paragraph",
      "text": "Initial data readout from Phase 1 VYD222 clinical trial planned for Q2 2023, including early insights into serum virus neutralizing activity",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a964b7a1-bbb6-4de1-a332-0bf5e1319768",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.018,
        "x": 0.959,
        "y": 0.969
      },
      "kind": "source-note",
      "text": "10",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b92be178-3144-4e76-9303-dd80bb9740a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.099,
        "w": 0.879,
        "x": 0.043,
        "y": 0.07
      },
      "kind": "title",
      "text": "INVIVYD IS POSITIONED TO POTENTIALLY FULFILL A LARGE UNMET NEED",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef24cf69-e8a1-44bc-8dbc-4b00e9d8a107",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "c71d1650-7012-4826-8d41-2bb5b4993bcd",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-10 propose Invivyd's solution and its potential to fulfill a large unmet need.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 7,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "3b35d58f-2d99-44a5-b484-2bf12410ffb9",
      "evidence": "Slides 7-10 discuss market sizing, ongoing trials, and proposed solutions.",
      "position": 1,
      "objective": "How can Invivyd's VYD222 address the unmet need?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}